| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e0ffe2f789b5d3c25aba9e68844541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1746b7b1abdf84162505bccc72a37be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6795ff81303e870114d26ca3cd0f6d67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56eb78d4f14a782fb3d63f8762985109
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bff7495fb74deb422e50c868c00a3c6b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00 |
| filingDate |
2011-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f5b9b7e8b04f3eaaaa31b4d45edae95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2324676204ef84c9ffef556d0970411
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16e2023d44eb370a8691352c3a822c16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_002fa8e86268fee5e2e3550fc2fd551d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8903aaee75839c15f5d83c9973b466a |
| publicationDate |
2013-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013196380-A1 |
| titleOfInvention |
In vitro process for the preparation of antibodies of the igg type |
| abstract |
An in vitro process for the preparation of antibodies of the IgG type, comprising the steps of: i. challenging dendritic cells obtained from a donor with an antigen against which the antibodies to be prepared are directed; ii. challenging CD4+ T cells obtained from the same donor with fragments of the antigen presented by the dendritic cells from step L, with the proviso that the dendritic cells are ones essentially not secreting interferon-γ (IFN-γ) and interleukin 12 (IL-12), to generate antigen-specific CD4+ Th2 cells; iii. challenging with the antigen a B cell population obtained from the same donor and including a sufficient proportion of naive B cells; and iv. contacting the antigen-specific CD4+ Th2 cells according to ii. with at least a fraction of the B cell population from iii. to form an antigen-specific plasma cell; v. immortalizing said antigen-specific plasma cell; and vi. isolating the IgG antibodies formed by said antigen-specific plasma cell. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021233913-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020099674-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020099674-A2 |
| priorityDate |
2010-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |